User profiles for Yusef Badi
Yusef BadiBenevolentAI, Imperial College London NHLI Verified email at ic.ac.uk Cited by 292 |
[HTML][HTML] Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthma
Background Patients with severe asthma may have a greater risk of dying from COVID-19
disease. Angiotensin converting enzyme-2 (ACE2) and the enzyme proteases, …
disease. Angiotensin converting enzyme-2 (ACE2) and the enzyme proteases, …
Sputum macrophage diversity and activation in asthma: role of severity and inflammatory phenotype
Background Macrophages control innate and acquired immunity, but their role in severe
asthma remains ill‐defined. We investigated gene signatures of macrophage subtypes in the …
asthma remains ill‐defined. We investigated gene signatures of macrophage subtypes in the …
Development of therapeutic splice-switching oligonucleotides
Synthetic splice-switching oligonucleotides (SSOs) target nuclear pre-mRNA molecules to
change exon splicing and generate an alternative protein isoform. Clinical trials with two …
change exon splicing and generate an alternative protein isoform. Clinical trials with two …
Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma
Accumulating evidence highlights links between iron regulation and respiratory disease.
Here, we assessed the relationship between iron levels and regulatory responses in clinical …
Here, we assessed the relationship between iron levels and regulatory responses in clinical …
Association of differential mast cell activation with granulocytic inflammation in severe asthma
Rationale: Mast cells (MCs) play a role in inflammation and both innate and adaptive
immunity, but their involvement in severe asthma (SA) remains undefined. Objectives: We …
immunity, but their involvement in severe asthma (SA) remains undefined. Objectives: We …
IL1RAP expression and the enrichment of IL‐33 activation signatures in severe neutrophilic asthma
Background Interleukin (IL)‐33 is an upstream regulator of type 2 (T2) eosinophilic
inflammation and has been proposed as a key driver of some asthma phenotypes. Objective To …
inflammation and has been proposed as a key driver of some asthma phenotypes. Objective To …
Mapping atopic dermatitis and anti–IL-22 response signatures to type 2–low severe neutrophilic asthma
Background Transcriptomic changes in patients who respond clinically to biological therapies
may identify responses in other tissues or diseases. Objective We sought to determine …
may identify responses in other tissues or diseases. Objective We sought to determine …
[HTML][HTML] Localization of Neuropeptide Gene Expression in Larvae of an Echinoderm, the Starfish Asterias rubens
…, EA Odekunle, M Zandawala, Y Badi… - Frontiers in …, 2016 - frontiersin.org
Neuropeptides are an ancient class of neuronal signaling molecules that regulate a variety
of physiological and behavioral processes in animals. The life cycle of many animals …
of physiological and behavioral processes in animals. The life cycle of many animals …
Airway expression of SARS-CoV-2 receptor, ACE2, and proteases, TMPRSS2 and furin, in severe asthma
Background Patients with severe asthma may have a greater risk of dying from COVID-19
disease caused by SARS-CoV-2 virus. Angiotensin converting enzyme 2 (ACE2) receptor and …
disease caused by SARS-CoV-2 virus. Angiotensin converting enzyme 2 (ACE2) receptor and …
Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma?
Background: Antibody-based therapies against Type 2 targets have been introduced for
severe eosinophilic asthma. Atopic dermatitis (AD) and asthma have similar inflammatory …
severe eosinophilic asthma. Atopic dermatitis (AD) and asthma have similar inflammatory …